Every generation or so, step changes in technology enable the creation of new infrastructure layers in healthcare that become foundational to everything that follows. We’ve seen this with electronic health records, revenue cycle management, and documentation and coding tools. We believe we are now at another such moment, one where healthcare can move beyond administrative efficiency and begin building infrastructure for clinical capacity itself.
Thesis is building that layer, enabling healthcare organizations to expand care team capacity at a fundamentally different scale than previously possible. In practice, this means that more can be done for more patients than ever before with minimal changes to existing workflows.
Thesis works by leveraging a unified platform to deploy AI agents in combination with expert clinicians to complete high-impact, high-ROI work for customer partners. The company is starting with clinical operations and care management, where it is already delivering strong results. Over time, we believe that Thesis’s model of AI agents working alongside expert clinicians can unlock a broader range of clinical capabilities, and we’re excited to partner with the team on that journey ahead.
Building this type of infrastructure is complex. It requires world-class technology, deep clinical expertise, and the ability to deliver results for sophisticated healthcare enterprises. Thesis co-founders Niren Gandra, M.D. (CEO) and Aditya Pandyaram (CPO) are uniquely suited to this task.
We were first introduced to Niren and Aditya during their time at Cedar, where we saw their strengths in understanding the market, building exceptional products, and delivering real value to customers. As we got to know them more closely over the years, we saw that they had a rare combination of clinical credibility, technical depth, and commercial creativity. We’ve seen this type of “clinical plus technology” combination be tremendously successful in many of the largest healthcare companies we’ve invested in over the years. So, when they came to us with this bold vision to reimagine the care teams of the future, we jumped right in with them.
We partnered with Thesis at the seed stage, and we’ve been side-by-side with the team as they’ve built the technology and the team. We’ve seen how deliberate they have been in designing every element of the platform and how thoughtful they have been in assembling a top-tier team. From the early days, when they were engaging with our network of advisors, to the customer traction they are seeing today, we’ve seen how strongly this concept resonates. The product-market fit couldn’t be clearer. In the early innings of commercialization, Thesis is already working with some of the nation’s largest physician groups, such as US Heart & Vascular, Springfield Clinic, Essen Health Care, and Allied Digestive Health. Beyond physician groups, Thesis is also expanding into partnerships with health systems and care teams at payers.
Since we led the seed round, our conviction in the team and the platform has only grown. That is why we are excited to be leading the $45 million Series A announced by the company today, with participation from CRV, Black Opal Ventures, and strategic healthcare angel investors. This capital will go toward accelerating the company’s commercial efforts, deepening its technology platform, and expanding its suite of care team agents.
The companies that define the next era of healthcare won’t be the ones with the most expansive vision statements. They’ll be the ones that become genuinely indispensable to the people doing the hardest work in medicine. Thesis is on that path, and we're proud to be building alongside them.